WST Stock Intrinsic Value – West Pharmaceutical Services Stock Rises Tuesday, Despite Underperforming Market
July 23, 2023
🌥️Trending News
Tuesday saw West Pharmaceutical Services ($NYSE:WST) Inc. stock rise by 0.25% to $384.59, despite the fact that its performance lagged behind that of the overall market. West Pharmaceutical Services Inc. is a global leader in providing innovative solutions to the pharmaceutical and biopharmaceutical industry. The company has a long history of creating products that meet the highest standards of quality and safety, and is committed to delivering innovative and cost-efficient solutions. West Pharmaceutical Services Inc. produces injection molded components, sterile drug delivery systems, and other related products for both the human and animal health markets. These products are used in a variety of healthcare settings, from products for hospital use to products used in home healthcare.
The company also provides contract manufacturing services for pharmaceutical and biopharmaceutical companies. Despite Tuesday’s rise, West Pharmaceutical Services Inc. is still underperforming the overall market. Investors may want to watch the stock closely to see how it responds to the latest market fluctuations. In the meantime, investors should also consider the company’s long-term growth prospects, as West Pharmaceutical Services Inc. is well-positioned to take advantage of any changes in the markets and continue to deliver innovative products and services.
Market Price
The stock opened at $383.7 and closed at $384.6, an increase of 0.3% from the previous day’s closing price of $383.6. The gain was significant given the downturn in the overall market, and a sign that investors are confident in the company’s prospects. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for WST. More…
| Total Revenues | Net Income | Net Margin |
| 2.88k | 552.1 | 19.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for WST. More…
| Operations | Investing | Financing |
| 710.9 | -288.2 | -293.6 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for WST. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.62k | 931.9 | 36.15 |
Key Ratios Snapshot
Some of the financial key ratios for WST are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 15.2% | 32.3% | 22.6% |
| FCF Margin | ROE | ROA |
| 17.1% | 15.2% | 11.3% |
Analysis – WST Stock Intrinsic Value
At GoodWhale, we analyze the fundamentals of WEST PHARMACEUTICAL SERVICES to give investors an unbiased assessment of the stock. Our proprietary Valuation Line indicates that the intrinsic value of the WEST PHARMACEUTICAL SERVICES share is approximately $355.9. The current market price for WEST PHARMACEUTICAL SERVICES stock is $384.6, which is a fair price, but slightly overvalued by 8.1%. Our analysis can help investors make more informed decisions about whether to buy, hold, or sell WEST PHARMACEUTICAL SERVICES stock. More…
Peers
The company operates in North America, Europe, Asia, and South America. Seikagaku Corp, Shenyang Xingqi Pharmaceutical Co Ltd, and Shenzhen Salubris Pharmaceuticals Co Ltd are all competitors of West Pharmaceutical Services Inc.
– Seikagaku Corp ($TSE:4548)
Seikagaku Corp is a Japanese company that specializes in the research and development of pharmaceuticals. The company has a market cap of 53.35B as of 2022 and a return on equity of 2.38%. Seikagaku Corp’s products include treatments for osteoarthritis, inflammatory diseases, and cancer.
– Shenyang Xingqi Pharmaceutical Co Ltd ($SZSE:300573)
Shenyang Xingqi Pharmaceutical Co Ltd is a pharmaceutical company with a market cap of 10.63B as of 2022. The company has a return on equity of 12.24%. The company’s main products are traditional Chinese medicines and western medicines. The company also has a research and development center which is responsible for the development of new products and the improvement of existing products. The company has a strong marketing network and a good reputation in the industry.
– Shenzhen Salubris Pharmaceuticals Co Ltd ($SZSE:002294)
Shenzhen Salubris Pharmaceuticals Co Ltd is a Chinese pharmaceutical company with a market cap of 37.86B as of 2022. The company’s ROE is 6.05%. Shenzhen Salubris Pharmaceuticals Co Ltd is engaged in the research, development, manufacture and sale of pharmaceutical products. The company’s products include drugs for the treatment of cardiovascular and cerebrovascular diseases, cancer, infections, digestive diseases and other diseases.
Summary
West Pharmaceutical Services Inc. enjoyed positive trading Tuesday, rising 0.25% to $384.59. Analysts consider its current performance underwhelming compared to the broader market, but suggest it may be a good opportunity to invest for those looking for lower risk/return ratios. The potential for growth is there, and investors should consider researching the stock further to assess whether it is a good fit for their portfolio.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
